Dopamine agents for hepatic encephalopathy

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 2, 2014, Pages

  Junker, Anders Ellekær ^a   Als Nielsen, Bodil ^b   Gluud, Christian ^b   Gluud, Lise Lotte ^c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE; LEVODOPA; PLACEBO;

CONSTIPATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; HALLUCINATION; HEADACHE; HEPATIC ENCEPHALOPATHY; HUMAN; MORTALITY; NAUSEA AND VOMITING; NEUROTRANSMISSION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 85013784559     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003047.pub3     Document Type: Review

References (68)

1. Koshy A, Pratap B, Datta DV. Prospective randomised controlled trial of L-dopa and hydrocortisone in fulminant hepatitis. Journal of the Association of Physicians of India 1982;30(9):613-4. [MEDLINE: 7184928]
2. Michel H, Cauvet G, Granier PM, Bali JP, Cuilleret A, Cuilleret G. Treatment of cirrhotic hepatic encephalopathy by L-dopa. A double-blind study of 58 patients [abstract]. Digestion 1977; Vol. 15:232-3.
3. Michel H, Solere M, Granier P, Cauvet G, Bali JP, Pons F, et al.Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial. Gastroenterology 1980;79(2):207-11. [MEDLINE: 6995221]
4. Morgan MY. Bromocriptine in the treatment of chronic hepatic encephalopathy. In: Capocaccia L, Fischer JE, Rossi-Fanelli F editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:255-65.
5. Morgan MY, Jakobovits AW, James IM, Lennox R, Sherlock S. Bromocriptine in the treatment of chronic portal systemic encephalopathy [abstract]. Gut 1978; Vol. 19, issue Suppl 2:A453.
6. Morgan MY, Jakobovits AW, James IM, Sherlock S. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 1980;78(4):663-70. [MEDLINE: 7353752]
7. Uribe M, Farca A, Marquez MA, Garcia Ramos G, Guevara L. Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial. Gastroenterology 1979;76(6):1347-51. [MEDLINE: 374177]
8. Vij JC, Tandon BN. Controlled trial of levodopa in fulminant hepatitis. Indian Journal of Medical Research 1979;69:624-8. [MEDLINE: PMID: 378825]
9. Catalano D, Trovato G, Vancheri F, Mazzone O. Bromocriptine in the treatment of chronic hepatic encephalopathy refractory to conventional treatment: crossover trial with levodopa-benserazide. Current Therapeutic Research 1982;32:544-54. [EMBASE 1982249532]
10. Datta DV, Maheshwari YK, Aggarwal ML. Levodopa in fulminant hepatic failure: preliminary report. American Journal of the Medical Sciences 1976;272:95-9. [MEDLINE: PMID: 961722]
11. Jorge AD, Sanchez D. Effect of L-dopa on hepatic coma [Die Wirkung des L-Dopa im Coma hepaticum]. Schweizerische Rundschau für Medizin Praxis 1973;62(27):868-72. [MEDLINE: 4578027]
12. Lunzer M, James IM, Weinman J, Sherlock S. Treatment of chronic hepatic encephalopathy with levodopa. Gut 1974;15(7):555-61. [MEDLINE: 4430473]
13. Messner M, Le Gall J-Y, Toulouse P, Javaudin L, Delamaire D, Brissot P, et al.Plasma ratio of branched chain/aromatic amino acids during treatment of chronic hepatic encephalopathy using lactulose/bromocriptine in a double blind procedure [EASL abstract]. Liver 1982;2(3 Pt 2):312. [EMBASE: 1983020208]
14. Pascual Izuel JM, Peces Serrano R, Hernandez Guio C. Role of bromocriptine in the treatment of chronic hepatic encephalopathy [Interes de la bromocriptina en el tratamiento de la encefalopatia hepatica cronica]. Revista Clinica Espanola 1979;155(3):219-21. [MEDLINE: 397554]
15. Trovato GM, Catalano D, Vancheri FS, Mazzone O. Successful use of amantadine and levodopa-benserazide in chronic portal systemic encephalopathy. A crossover trial with conventional therapy. Current Therapeutic Research Clinical and Experimental 1982;31:625-37. [EMBASE 1982138453]
16. Ubiria J, Morales M, Vila A, Farre A, Balanzo J. Treatment of chronic portosystemic encephalopathy with bromocriptine [Tratamiento de la encefalopatía crónica portosistémica (E.C.P.S.) con bromocriptina]. Revista Espanola de Las Enfermedades del Aparato Digestivo 1980;58(1):21-4. [MEDLINE: 7403629]
17. Uribe M, Garcia Ramos G, Ramos M, Valverde C, Marquez MA, Farca A, et al.Standard and higher doses of bromocriptine for severe chronic portal-systemic encephalopathy. American Journal of Gastroenterology 1983;78(8):517-22. [MEDLINE: 6881119]
18. Uribe M, Marquez MA, Guevara L, Garcia Ramos G. Bromocriptine for severe chronic portal systemic encephalopathy [abstract]. Gastroenterology 1982;82:1201.
19. Abraldes JG, Bosch J. The treatment of acute variceal bleeding. Journal of Clinical Gastroenterology 2007;41(Suppl 3):S312-S317. [PUBMED: 17975482]
20. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD003044.pub2]
21. Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, et al.Review article: the design of clinical trials in hepatic encephalopathy -an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Alimentary Pharmacology & Therapeutics 2011;33(7):739-47. [PUBMED: 21306407]
22. Basile AS, Jones EA, Skolnick P. The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptor ligands. Pharmacological Reviews 1991;43(1):27-71. [MEDLINE: 91239624]
23. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al.Rifaximin treatment in hepatic encephalopathy. New England Journal of Medicine 2010;362(12):1071-81. [PUBMED: 20335583]
24. Becker MP, Balagtas CC. Marginal modelling of binary cross-over data. Biometrics 1993;49:997-1009. [MEDLINE: PMID: 8117910]
25. Blei A. Hepatic encephalopathy. In: Bircher J, Benhamou J-P, McIntyre N, Rizzetto M, Rodés J editor(s). Clinical Hepatology. 2nd Edition. Vol. 1, Oxford: Oxford University Press, 1999:765-83.
26. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.
27. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive -Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98.
28. Conn H, Lieberthal M. The Hepatic Coma Syndromes and Lactulose. Baltimore: Williams & Wilkins, 1979.
29. Cordoba J, Alonso J, Rovira A, Jacas C, Sanpedro F, Castells L, et al.The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. Journal of Hepatology 2001;35:598-604. [MEDLINE: PM 11690705]
30. Copenhagen Trial Unit. TSA -Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 4 September 2012).
31. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9. [MEDLINE: PMID: 11914310]
32. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy -definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-21. [MEDLINE: PM 11870389]
33. Gitlin N. Hepatic encephalopathy. In: Zakim D, Boyer T editor(s). Hepatology. A Textbook of Liver Disease. III Edition. Vol. 1, Philadelphia: WB Saunders Company, 1996:605-17.
34. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). Art. No.: LIVER 2013, issue 12.
35. Guerit JM, Amantini A, Fischer C, Kaplan PW, Mecarelli O, Schnitzler A, et al.Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver International 2009;29(6):789-96. [PUBMED: 19638107]
36. Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?. Journal of Hepatology 2000;32:1035-8. [MEDLINE: PMID: 10898326]
37. Higgins JPT, White IR, Wood AM. Imputation methods for missing outcome data in meta-analysis of clinical trials. Clinical Trials 2008;5:225-39.
38. Higgins JP, Whitehead A, Simmonds M. Sequential methods for random-effects meta-analysis. Statistics in Medicine 2011;30(9):903-21. [PUBMED: 21472757]
39. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
40. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR and ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
41. Jover R, Company L, Gutierrez A, Zapater P, Perez-Serra J, Girona E, et al.Minimal hepatic encephalopathy and extrapyramidal signs in patients with cirrhosis. American Journal of Gastroenterology 2003;98:1599-604. [MEDLINE: PMID: 12873585]
42. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
43. Les I, Doval E, Garcia-Martinez R, Planas M, Cardenas G, Gomez P, et al.Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology 2011;106(6):1081-8. [PUBMED: 21326220]
44. Lizardi-Cervera J, Almeda P, Guevara L, Uribe M. Hepatic encephalopathy: a review. Annals of Hepatology 2003;2:122-30. [MEDLINE: PMID: 15115963]
45. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
46. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. American Academy of Neurology 2002;58:11-7. [MEDLINE: PMID: 12391377]
47. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
48. Parkes JD, Sharpstone P, Williams R. Levodopa in hepatic coma. Lancet 1970;2(7687):1341-3. [MEDLINE: 4098911]
49. Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A. Pharmacotherapy for hepatic encephalopathy. Drugs 2010;70(9):1131-48. [PUBMED: 20518580]
50. Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, Mapelli D, et al.Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver International 2009;29(5):629-35. [PUBMED: 19302444]
51. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
52. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
53. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
54. Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
55. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
56. Spahr L, Vingerhoets F, Lazeyras F, Delavelle J, DuPasquier R, Giostra E, et al.Magnetic resonance imaging and proton spectroscopic alterations correlate with parkinsonian signs in patients with cirrhosis. Gastroenterology 2000;119:774-81. [MEDLINE: 10982772]
57. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al.SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158:200-7.
58. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, et al.SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ (Clinical Research Ed.) 2013;346:e7586.
59. STATACorp LP, Texas USA. STATA 12. STATACorp LP, Texas USA, 2012.
60. Stowe R, Ives N, Clarke CE, van Hilten, Ferreira J, Hawker RJ, et al.Dopamine agonist therapy in early Parkinson's disease. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006564.pub2; PUBMED: 18425954]
61. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al.Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology 2009;38(1):276-86.
62. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
63. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). http://ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 23 April 2013).
64. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75. [PUBMED: 18083463]
65. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86. [DOI: 10]
66. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012;61(2):297-310. [PUBMED: 22147550]
67. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601-5. [PUBMED: 18316340]
68. Als-Nielsen B, Gluud LL, Gluud C. Dopaminergic agonists for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD003047.pub2]